Spark I Acquisition

SPKL

Spark Therapeutics, Inc. is a developer of gene therapy treatments, which treat debilitating genetic diseases. It is a subsidiary of Hoffmann-La Roche.

Spark I Acquisition has been a target of short sellers for a while. The current short interest of 0.06% is roughly at the average of the last 12 months (0.10%).